Roivant Sciences Ltd. filings document material events for a Nasdaq-listed Bermuda biopharmaceutical company with common shares registered under the ticker ROIV. The company’s recent Form 8-K disclosures cover quarterly financial results, preliminary liquidity information, share repurchases, Regulation FD updates and exhibits tied to clinical programs at subsidiaries such as Priovant Therapeutics.
Its filings also record material definitive agreements and amendments, including the Genevant Sciences settlement agreement involving lipid nanoparticle delivery technology, as well as shareholder voting results from the annual general meeting. Governance disclosures include director elections, auditor ratification and other proxy-related voting matters, while clinical exhibits describe programs such as brepocitinib in autoimmune and inflammatory diseases.
Roivant Sciences Ltd. (ROIV) filing a Form 144 notifies an intended sale of 683,818 common shares via Morgan Stanley Smith Barney on 09/19/2025, with an aggregate market value reported as $10,220,412.21. The shares were acquired and paid for on 09/19/2025 through a stock option exercise with cash payment. The filer also reported three prior open-market sales by Eric Venker totaling 300,000 shares during June–August 2025 for combined gross proceeds of $3,452,000.00. The notice includes the standard representation that the seller is unaware of undisclosed material adverse information.
Matthew Gline, listed as Director and CEO of Roivant Sciences Ltd. (ROIV), reported a purchase of 3,315 common shares on 09/18/2025 at a weighted average price of $15.07 per share. After this transaction the filing shows Mr. Gline beneficially owns 17,287,081 common shares. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Gline.
Roivant Sciences Ltd. reported that its subsidiary Priovant Therapeutics achieved positive results in the Phase 3 VALOR study of brepocitinib in dermatomyositis, a serious autoimmune muscle disease. The company released a detailed press release and an investor presentation describing these Phase 3 results.
Roivant also scheduled a conference call and webcast at 8:00 a.m. E.D.T. on September 17, 2025 to discuss the VALOR data, and posted the related presentation on the investor relations section of its website. These materials are furnished as exhibits to the report, giving investors additional information on the study outcome.
Roivant Sciences Ltd. reported the results of shareholder votes demonstrating routine corporate governance outcomes. Shareholders re-elected the individuals named to serve as Class I directors to hold office until the annual general meeting following the fiscal year ending March 31, 2028. Shareholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers as disclosed in the proxy statement. The advisory vote tallied 316,651,402 votes in favor, 203,244,184 against and 64,550,276 abstentions; there were 44,227,813 broker non-votes reported. The filing includes the cover page interactive data file as an exhibit.
Roivant Sciences director Vivek Ramaswamy reported multiple open-market sales of the company's common shares on September 3–5, 2025. The Form 4 shows he disposed of 1,195,000 shares on 09/03/2025 at a weighted-average price of $12.50, 194,933 shares on 09/04/2025 at $12.92 weighted-average, and 385,816 shares on 09/05/2025 at $12.96 weighted-average, for total reported disposals of 1,775,749 shares. After these transactions he beneficially owns 35,508,359 shares directly and holds an additional 13,357,857 shares indirectly. Footnotes state the reported prices are weighted averages reflecting multiple transactions in specified price ranges, and the form is signed by an attorney-in-fact.
Roivant Sciences Ltd. reported that it has provided an update on the Graves’ Disease development program at its subsidiary, Immunovant, Inc. The company issued a press release and made it available as an exhibit, focusing on Immunovant’s proof-of-concept study in Graves’ Disease.
Roivant also posted an investor presentation covering the update on Immunovant’s Graves’ Disease proof-of-concept study on its investor relations website and scheduled a conference call and webcast to discuss remission data from Immunovant’s Graves’ Disease trial at 4:30 p.m. E.D.T. Both the press release and the presentation are included as exhibits to the report, while the website content itself is not incorporated.
Richard Pulik, identified as CFO and a director of Roivant Sciences Ltd. (ROIV), reported a disposition of 2,340 common shares on 08/28/2025 at a price of $11.94 per share. The filing states this sale represents a net settlement by the issuer to satisfy tax withholding obligations related to previously granted restricted stock units (RSUs). Following the reported transaction, Mr. Pulik beneficially owned 393,978 shares. The Form 4 was signed by an attorney-in-fact on 09/02/2025.
Richard Pulik, Chief Financial Officer of Roivant Sciences Ltd. (ROIV), reported the disposition of 1,235 common shares on 08/20/2025 at a price of $11.72 per share, leaving him with 396,318 shares beneficially owned. The filing explains this was a net settlement of previously granted restricted stock units to satisfy tax withholding obligations upon vesting. The transaction was reported on a single-person Form 4 and executed by an attorney-in-fact.
Eric Venker, President & Immunovant CEO of Roivant Sciences Ltd. (ROIV), reported multiple Section 16 transactions dated 08/20/2025. The filing shows a net settlement of 7,051 restricted stock units to satisfy tax withholding at a weighted average price of $11.72, a sale of 100,000 shares at a weighted average price of $11.72 effected under a Rule 10b5-1 trading plan adopted on 06/25/2024, and an award/recording of 100,000 stock options with an exercise price of $3.85. After the transactions, the reporting person’s direct common stock holdings are shown as 1,653,585 and then 1,753,585 shares at different steps; total derivative securities beneficially owned following the reported option award are reported as 8,038,897 (direct). The form includes an explanation that the RSU transfer was a net settlement for taxes and that the sales were pursuant to the 10b5-1 plan.
Roivant Sciences Ltd. (ROIV) Form 144 notifies proposed sale of 100,000 common shares to be executed on 08/20/2025 through Rockefeller Financial LLC on NASDAQ, with an aggregate market value listed as $1,172,120.12. The shares were shown as acquired by exercise of options on 08/20/2025 (grant date 04/20/2022) from Roivant Sciences Ltd., with payment by wire. The filer also disclosed multiple recent sales by Eric Venker totaling 1,330,148 shares between 05/20/2025 and 07/21/2025 with gross proceeds reported for each transaction.